Birchview Capital »

Altimmune shares owned by Birchview Capital

Quarter-by-quarter ownership of Altimmune (ALT) shares owned by Birchview Capital from 13F filings

Historical chart of Birchview Capital investment in Altimmune

Tip: Access up to 7 years of quarterly data

All positions including Altimmune held by Birchview Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Altimmune by Birchview Capital

Quarter filed Position value Share count Share price at filing
2026-06-30 $464k 153k 3.04

More positions owned by Birchview Capital

Kla Corporation Com New (KLAC)
Bristol Myers Squibb (BMY)
Lam Research Corporation Com New (LRCX)
Solid Biosciences Com New (SLDB)
Intellia Therapeutics (NTLA)
Biodesix
Stoke Therapeutics (STOK)
Encana Corporation (OVV)
Nektar Therapeutics (NKTR)
Corcept Therapeutics Incorporated (CORT)
Neurocrine Biosciences (NBIX)
Prothena Corp SHS (PRTA)
ACADIA Pharmaceuticals (ACAD)
Protagonist Therapeutics (PTGX)
Compass Therapeutics (CMPX)

View all positions for Birchview Capital

Top funds holding Altimmune

BlackRock
Deep Track Capital
TCG Crossover Management
Vanguard Capital Management
Vanguard Portfolio Management
State Street Corporation
Marshall Wace
Viking Global Investors
RA Capital Management
Geode Capital Management
Woodline Partners
Millennium Management
Susquehanna International
Trails Edge Capital Partners
Nuveen

View all funds holding Altimmune